Voraxaze
Drug: Voraxaze
Generic molecule: glucarpidase
Company: BTG International
Approval date: Jan. 17
The scoop: The year's first drug approval went to the U.K.'s BTG for Voraxaze, a new treatment designed to reduce methotrexate concentrations in the plasma of patients receiving chemotherapy. The market is only estimated to be about $15 million.
